Motzer, Robert J http://orcid.org/0000-0001-6925-2327
Escudier, Bernard
McDermott, David F
Arén Frontera, Osvaldo
Melichar, Bohuslav
Powles, Thomas
Donskov, Frede
Plimack, Elizabeth R
Barthélémy, Philippe
Hammers, Hans J
George, Saby
Grünwald, Viktor
Porta, Camillo
Neiman, Victoria
Ravaud, Alain
Choueiri, Toni K http://orcid.org/0000-0002-9201-3217
Rini, Brian I
Salman, Pamela
Kollmannsberger, Christian K
Tykodi, Scott S
Grimm, Marc-Oliver
Gurney, Howard
Leibowitz-Amit, Raya
Geertsen, Poul F
Amin, Asim
Tomita, Yoshihiko
McHenry, M Brent
Saggi, Shruti Shally
Tannir, Nizar M
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
https://doi.org/10.1136/jitc-2022-005445
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2020-000891
Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214.
https://doi.org/10.1200/jco.2023.41.6_suppl.659
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.363
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
https://doi.org/10.1136/jitc-2021-004316
556 Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): analysis from CheckMate 214
https://doi.org/10.1136/jitc-2022-sitc2022.0556
Update on the Biology and Management of Renal Cell Carcinoma
https://doi.org/10.1136/jim-2018-000918
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
https://doi.org/10.1136/esmoopen-2020-001079
Funding for this research was provided by:
Bristol Myers Squibb and ONO Pharmaceutical Company Limited